March 2026 Research Update

This month added mixed but useful real-world signals about immune-targeted treatments in adult-onset Still's disease (AOSD). In a small canakinumab study, the early primary goal was not met, but several measures looked better later on, alongside steroid tapering for some people. In a retrospective comparison, adding tocilizumab to a short burst of high-dose steroids was linked with faster remission and more people stopping steroids later, but the design cannot prove the drug caused the difference. [1] [2]

Canakinumab (an IL-1beta blocking biologic) was tested in 14 Japanese adults in a single-arm Phase III study, meaning there was no comparison group. The week 8 primary endpoint was not met, but by week 28 the assessed patients showed improvement across multiple response measures and some were able to taper oral glucocorticoids during weeks 8 to 28. Safety reporting included treatment-emergent side effects in all participants and serious infections in 3 patients, which resolved. [1]

Tocilizumab (an IL-6 receptor blocking biologic) was studied in routine care records where it was paired with a short course of high-dose glucocorticoids and compared with standard-dose glucocorticoids plus conventional immune-suppressing drugs. The tocilizumab group reached remission faster in the first months and had higher long-term steroid discontinuation, with larger drops in inflammation blood tests reported in that group. Because the groups were not randomized and treatments differed in more than one way, it remains unclear how much of the difference was due to tocilizumab itself versus other factors such as the steroid approach or patient selection. [2]

A separate report described combining anakinra (an IL-1 blocker) with baricitinib (a JAK inhibitor) as a successful approach, but the available summary did not include details such as the number of patients, what improved, or how outcomes were measured. This adds to the idea that combination immune-targeting is being tried in Still's disease, but it cannot be interpreted beyond that without more information. [3]

For patients, these studies mainly add context about how biologics and other immune-targeted medicines are being evaluated in AOSD rather than providing a clear, definitive answer about which option works best. Canakinumab showed later improvements and some steroid tapering in a small study, but the early primary goal was not reached and infections were reported, so the picture is still developing. The tocilizumab findings point toward faster control and less long-term steroid use in one center's experience, but the comparison was not randomized, so it is not proof of cause and effect. The combination anakinra plus baricitinib report signals ongoing experimentation with pairing targets, but details were too limited to judge what it might mean for others. [1] [2] [3]

This month, studies focused on macrophage activation syndrome (MAS) in Still's disease in two practical directions: how to spot higher risk early and what was tried when MAS was severe. A multi-hospital model used a small set of admission findings to predict who developed MAS in the hospital, and it separated people into risk groups with clearly different MAS rates. In parallel, small reports described plasma exchange or targeted immune blockers for difficult MAS cases, showing possible short-term improvement in some patients but with outcomes that can vary. [4] [5] [6]

The MAS prediction study built a bedside score using five baseline items: ferritin, spleen enlargement, platelet count, total cholesterol, and ESR. In the independent test set, the model had an AUC of 0.839, and the risk categories showed different MAS rates, including 42.1% in the high-risk group. This suggests that routine admission information may help flag who needs closer attention for MAS, though the study did not test whether using the tool changes outcomes. [4]

In a five-patient case series of AOSD with MAS, adding therapeutic plasma exchange was followed by fever and rash resolving and inflammatory labs trending down, without needing steroid increases during and immediately after the exchanges. Four patients had very low CRP by 1 month, while one patient later died from CMV infection despite MAS improvement. With no comparison group and only five patients, this is best viewed as an early description of how plasma exchange was used in one center rather than a proven standard approach. [5]

One case report described a woman with MAS linked to AOSD who did not respond well enough to earlier treatments including corticosteroids and IL-1 blockade. She achieved symptom resolution after IFN-gamma blockade (emapalumab) and then adding a JAK inhibitor (ruxolitinib), while continuing anakinra. A single case cannot show what would happen in most patients, but it illustrates which immune pathways are being targeted when MAS is hard to control. [6]

For patients and caregivers, this group of studies helps clarify that MAS remains a major focus in AOSD research, with efforts aimed at earlier recognition and finding options for severe, hard-to-control cases. The risk score work may matter in the future if it is tested prospectively and shown to improve decisions or outcomes, but right now it is mainly a research tool. The plasma exchange series and the emapalumab plus ruxolitinib case report show approaches that were followed by improvement in the reported patients, while also reminding that severe inflammation often overlaps with infection risk and that results can differ person to person. [4] [5] [6]

This month strengthened the idea that measuring and recognizing Still's disease involves both structured criteria and careful exclusion of other conditions, especially when symptoms are unusual. A large cohort study proposed a simple set of clinical features plus CRP to label active versus inactive AOSD, and it performed well in separate validation groups. Case reports highlighted that AOSD can present without a rash, can overlap with other joint findings like CPPD crystals, and can include uncommon problems like nerve symptoms, all of which can complicate diagnosis and monitoring. [7] [8] [9] [10] [11]

The activity criteria study defined a five-item set: fever, rash, arthritis, patient global assessment of at least 2 cm, and CRP greater than 10 mg/L. Active disease was defined as fever plus one other item, or (without fever) at least three of the remaining items, while inactive disease required none of the five. The criteria showed strong separation between active and inactive disease in both the Italian cohort and an external trial dataset, which may support more consistent communication about disease activity in research and possibly in future routine tracking. [7]

Several case reports emphasized how strongly ferritin can rise in AOSD and how it can move down when inflammation improves, even when the presentation is atypical. One man in the UAE had prolonged fever, joint pain, liver inflammation, and very high ferritin, with rapid improvement after high-dose steroids once other causes were excluded. Another report described the Wissler-Fanconi variant (AOSD without rash) where fever improved within 72 hours of steroids and ferritin normalized during follow-up. [8] [10]

Two cases show that unusual features can appear alongside AOSD and create diagnostic uncertainty. One patient had calcium pyrophosphate crystals in a knee joint (which can point toward a different joint condition) but still fit AOSD after other causes were excluded, and later improved on IL-1 targeted therapy. Another patient presented with progressive motor nerve problems and improved after steroids, colchicine, and early anakinra, suggesting that nerve involvement can occur even though it is rare. [9] [11]

One additional diagnostic study this month was not about AOSD, but it helps interpret a common point of confusion in inflammatory disease workups: antibody tests like RF and ACPA. Across 11 European centers, the study found that results can vary widely depending on which assay and cut-off is used, and that using specificity-based thresholds and result intervals reduced variability and made test interpretation more consistent. This matters for people being evaluated for inflammatory arthritis in general, because these blood tests may influence whether rheumatoid arthritis is considered versus other causes of joint symptoms. [12]

For patients, these studies mostly add clarity about how AOSD activity might be described more consistently and why diagnosis can still be challenging when symptoms do not look classic. The proposed activity criteria may matter later by giving researchers and clinics a shared, simple checklist to describe active versus inactive disease, but it is not itself a treatment plan. The case reports reinforce that ferritin often tracks with inflammation in AOSD, while also showing that other findings (no rash, CPPD crystals, nerve symptoms) can blur the picture and require careful exclusion of other causes. The RF/ACPA assay study does not apply directly to Still's disease, but it supports a practical point: some blood test results depend strongly on how the test is done, so interpretation is not always straightforward. [7] [8] [10] [9] [11] [12]

This month included early research that tries to explain why Still's-like inflammation happens in some people, and an epidemiology study that used Still's disease as part of a comparison group for another inflammatory condition. A family with a Still's-like syndrome was linked to a specific RIPK3 gene change that increased inflammatory cell-death signaling in lab tests. Separately, a registry study in older adults reported higher cancer risk in VEXAS syndrome compared with a control group that included Still's disease, which helps place Still's disease among other inflammatory diagnoses that can resemble each other. [13] [14]

In a three-generation family (3 affected people), researchers found a heterozygous RIPK3 p.Q134K variant and showed it was gain-of-function in functional tests. The variant increased RIPK3 activity and promoted necroptosis (an inflammatory form of cell death) through MLKL phosphorylation, and patient immune cells showed higher inflammatory pathway signals and higher IL-6 and TNF-alpha that were suppressed by RIPK3 inhibition in the lab. This does not establish a common cause of typical AOSD, but it gives a concrete example of a pathway that can drive Still's-like autoinflammation. [13]

A registry-based cohort study of VEXAS syndrome compared cancer rates in 90 people with VEXAS versus 174 disease controls older than 60 years, where the control group included people with Still's disease. VEXAS had a higher overall cancer risk than the control group, and certain VEXAS features were linked with higher risk within that condition. Because the study question was about VEXAS rather than AOSD, it does not provide an AOSD-specific cancer risk estimate, but it highlights why some Still's-like presentations may lead clinicians to consider genetic or hematologic look-alikes such as VEXAS in older adults. [14]

For patients with typical adult-onset Still's disease, these studies mainly expand scientific understanding rather than changing current diagnosis or treatment. The RIPK3 family report may matter in the future by pointing to a specific inflammatory pathway that can produce a Still's-like illness, but it was based on 3 people in one family and lab testing. The VEXAS cancer-risk paper is about a different condition that can sometimes mimic systemic inflammation, and it used Still's disease as part of its comparison group rather than studying Still's disease directly, so it should not be read as a cancer-risk result for AOSD. [13] [14]